BioEclipse collaboration with Spannerwerks

Written By Guest User

April 28, 2020

BioEclipse recently announced they will collaborate with Spannerwerks, LLC, to prepare for the upcoming Phase 1 clinical trial for CRX100. Spannerwerks worked with BioEclipse to complete the IND filing for CRX100.

“CRX100 is an important step forward in cancer immunotherapy and we are proud to work with BioEclipse as it advances this technology out of the laboratory and into the clinic,” said Dara Lockert, Executive Director of Spannerwerks.

#oncology #clinicaltrials #clinicaltrials

https://lnkd.in/gVuaTd

Guest User
Previous

A COVID-19 Planning Approach
Next

Spannerwerks Logo